Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

New Therapy Commercialization Grant (NTCG) and Epilepsy Seal of Innovation Award

Grants and Awards to USA, Canada, and International Researchers for
Research that Leads to New Treatments for People with Epilepsy

Agency Type:

Foundation / Corporation

Funding Source:

Add to My Calendar 

Epilepsy Foundation

LOI Date:

02/01/18

Deadline Date:

04/20/18

Description:

Request a Grant Writer

Grants and awards to USA, Canada, and International researchers with an advanced degree (i.e., MD, PhD, MS, or PharmD) for scientific research projects that could result in new treatments for people with epilepsy. The goal of this program is to accelerate therapies onto the market in a timeframe that matters.

ETP provides new therapy commercialization grants (NTCG) to support later-stage development projects past proof of concept stages. (See below* for more information on the New Therapy Commercialization Grants.) For projects that are beyond the resources of the Epilepsy Foundation, applicants can also apply for an Epilepsy Innovation Seal of Excellence award (SEAL). The SEAL is not a grant program but an official housekeeping seal of approval that a team can use to generate further venture capital interest. The SEAL awards undergo the same application and review process as the NTCG.

Areas of interest for the Foundation include:

- Novel approaches to treatment.
- Platform technology to advance screening techniques that can be utilized by multiple laboratories, including utility of techniques for early proof-of-concept trials.
- Adaptation of treatment in development for another therapeutic area to assess utility for epilepsy (while maintaining patent protection).

*More on the New Therapy Commercialization Grants:

These grants provide up to $350,000 for a maximum of 2 years to support the development of more effective therapies by serving as a catalyst for moving innovative therapies from the laboratory to the patient. Note that preference will be given to proposals that already have a commercial partner engaged to assist with development and to proposals that have committed or matched funding from the sponsoring institution, commercial partner or other third-party source. For the New Therapy Commercialization Grants, applicants must demonstrate background work beyond the proof of concept / basic science discovery stage.

The Foundation supports projects spanning diagnostics and devices to small molecules and biologics. For programs that seek to develop diagnostics and/or devices, projects must be in later stage feasibility testing or in the proof of value stage (i.e. there should be a minimal viable product (MVP) prototype with a product IFU (instructions for use) to be competitive. For programs that seek to develop potential drugs through small molecules and biologics, there must be at least one lead compound identified, which may be at the pre-IND (Investigational New Drug application) to be competitive for a New Therapy Commercialization Grant. Investigators of drugs are strongly advised to have their compounds screened, as appropriate, by the NINDS ETSP Program prior to applying.

GrantWatch ID#:

GrantWatch ID#: 180289

Estimated Size of Grant:

New Therapy Commercialization grants are up to $350,000.

The Epilepsy Innovation Seal of Excellence Award comes with no award dollars but an official housekeeping seal of approval that can be used to generate further venture capital funds.

Term of Contract:

New Therapy Commercialization grants are provided for two years.

Additional Eligibility Criteria:

Eligibility for both the New Therapy Commercialization Grant and Epilepsy Innovation Seal of Excellence Award:

Investigators must hold a relevant advanced degree (MD, PhD, MS, PharmD), and have completed all research training appropriate to the project proposed. Investigators may come from public and/or private sectors. The Foundation also considers international applications.

Pre-Application Information:

Letters of Intent due: February 1, 2018
Full Grant Proposal due: April 20, 2018

Click on the link in the Supporting Documents section below to download the instructions on how to apply.

More Information:

- https://www.epilepsy.com/make-difference/research-and-new-therapies/innovation/epilepsy-therapy-project
- https://www.epilepsy.com/make-difference/research-and-new-therapies/innovation/epilepsy-therapy-project/new-therapy

Contact Information:

Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.

Click here to apply via proposalCENTRAL: https://proposalcentral.altum.com/

For help with electronic application process, please contact the help desk for proposalCENTRAL: pcsupport@altum.com or 1-800-875-2562.

For questions, contact sdumanis@efa.org or grants@efa.org.

URL for Full Text (RFP):

Geographic Focus:

USA: Alabama;   Alaska;   Arizona;   Arkansas;   California;   Colorado;   Connecticut;   Delaware;   Florida;   Georgia;   Hawaii;   Idaho;   Illinois;   Indiana;   Iowa;   Kansas;   Kentucky;   Louisiana;   Maine;   Maryland;   Massachusetts;   Michigan;   Minnesota;   Mississippi;   Missouri;   Montana;   Nebraska;   Nevada;   New Hampshire;   New Jersey;   New Mexico;   New York City;   New York;   North Carolina;   North Dakota;   Ohio;   Oklahoma;   Oregon;   Pennsylvania;   Rhode Island;   South Carolina;   South Dakota;   Tennessee;   Texas;   Utah;   Vermont;   Virginia;   Washington, DC;   Washington;   West Virginia;   Wisconsin;   Wyoming

USA Territories: American Samoa (USA)   Guam (USA)   Puerto Rico (USA)   Virgin Islands (USA)   Northern Mariana Islands (USA)

USA Compact Free Associations: The Federated States of Micronesia (USA)   Marshall Islands (USA)   Republic of Palau (USA)

Canada: Alberta   British Columbia   Manitoba   New Brunswick   Newfoundland and Labrador   Northwest Territories   Nova Scotia   Nunavut   Ontario   Prince Edward Island   Quebec   Saskatchewan   Yukon

Israel

International country outside of the USA, Israel and Canada.